Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

A bladder ultrasound gives providers clues about how the bladder expands and holds urine. This article lists conditions ...

Patients with muscle-invasive bladder cancer who underwent whole pelvis radiation showed improved cancer-specific survival and overall survival.

Bladder cancer is the ninth most common cancer worldwide, and the number of diagnosed incident cases is set to increase.

Lower abdominal visceral fat area (VFA), older age, and prolonged surgery are independent risk factors for developing ...

Balversa (erdafitinib) marks the first and only bladder cancer therapy to target FGFR3 alterations, with a demonstrated increase in overall survival from 7.8 months to 12.1 months. On Nov. 6, 2024, ...

The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years ...

A recent study reveals that extended lymphadenectomy offers no survival advantage over standard lymphadenectomy for patients ...

Men who undergo prostate cancer treatment face a greatly increased risk of life-altering, long-term complications, a ...

This partnership unites the expertise of KFSHRC’s Urology Department with BCRC’s research capabilities to advance ...